Gisa Ellrichmann

TL;DR: The ability of dimethylfumarate to activate nuclear factor (erythroid-derived 2)-related factor 2 may offer a novel cytoprotective modality that further augments the natural antioxidant responses in multiple sclerosis tissue and is not yet targeted by other multiple sclerosis therapies.

TL;DR: A pivotal role of the RAS is suggested in autoimmune inflammation of the central nervous system and RAS blockade is identified as a potential new target for multiple sclerosis therapy.

TL;DR: Prolonged tocilizumab therapy may be safe and effective from early treatment phases onward for otherwise therapy-resistant highly active NMO and NMO spectrum disorder.

TL;DR: Investigating the therapeutic efficacy of DMF in R6/2 and YAC128 HD transgenic mice, which mimic many aspects of HD and are characterized by an enhanced generation of free radicals in neurons, concluded that DMF may exert beneficial effects in mouse models of HD.

TL;DR: Analyses in the animal model of experimental autoimmune encephalomyelitis (EAE) demonstrate that laquinimod reduces infiltration of leukocytes into the central nervous system, induces a Th1 to Th2/3 shift, and suppresses Th17 responses, consistent with immunomodulatory properties.